Adaptimmune Therapeutics PLC ADAPY

0.03 0.01 50.00% as of 25 Sep
Market cap
$14.6M
P/E
0.0×

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
181.47 208.26 205.13 89.54 368.22 369.58 204.61 146.94 151.61 25.95
Receivables
1.48 0.21 0.19 20.67 0.14 0.75 7.44 0.82 14.38 10.47
Inventory
— — — — — — — — 7.32 —
Other current assets
15.80 21.72 25.77 30.95 29.80 45.13 43.33 59.79 13.73 8.60
Total current assets
198.75 230.18 231.10 120.49 398.15 415.46 255.37 207.55 187.04 45.31
Property, Plant, Equpment (Net)
27.90 40.68 36.12 31.07 27.78 30.49 53.52 50.95 31.31 7.80
Goodwill and Intangible Assets (Total)
1.27 1.34 1.47 2.20 1.73 1.00 0.44 0.33 8.52 0.02
Long-term assets (Other)
4.02 4.25 4.10 4.50 4.60 1.72 1.57 3.03 2.07 1.73
Total non-current assets
35.76 50.96 45.64 61.05 52.99 54.09 73.55 75.06 59.38 18.05
Total Assets
234.52 281.15 276.74 181.54 451.14 469.55 328.92 282.62 246.42 63.36
Accounts Payable
11.35 8.38 4.08 6.36 6.39 8.11 4.75 8.13 40.98 16.61
Accrued Expenses
17.53 27.20 20.35 23.36 27.08 29.91 31.22 30.30 32.92 —
Current Revenue (Deferred)
11.39 38.74 — 2.13 2.83 22.20 23.52 28.97 12.30 —
Other current liabilities
26.91 65.94 20.35 25.49 29.91 52.11 2.29 — 6.85 0.70
Total current liabilities
40.27 74.31 24.44 34.34 39.07 62.54 64.50 72.79 64.85 22.24
Long Term Debt (Total)
— — — 22.97 20.94 23.15 20.35 — 50.24 —
Non-current Revenue (Deferred)
24.96 — — — 49.26 177.22 160.89 149.06 95.82 —
Non-current Liabilities (Other)
3.14 3.85 5.41 0.60 0.64 0.67 1.30 1.40 3.15 —
Total non-current liabilities
28.10 3.85 5.41 23.56 70.84 201.04 182.54 170.32 168.53 9.15
Total liabilities
68.37 78.16 29.85 57.91 109.92 263.59 247.04 243.10 233.38 31.39
Additional Paid In Capital
341.20 455.40 574.21 585.62 935.71 959.61 990.66 1,064.57 828.22 829.99
Common Stock (Net)
0.68 0.85 0.94 0.94 1.33 1.34 1.40 1.87 2.09 2.16
Retained Earnings
(161.49) (231.63) (318.50) (455.66) (585.76) (743.85) (909.30) (1,023.17) (938.50) (914.45)
Shareholders Equity (Other)
— — — — — — — — 131.01 131.01
Common Equity (Total)
166.14 202.98 246.89 123.64 341.23 205.96 81.88 39.51 13.04 31.97
Shareholders Equity (Total)
166.14 202.98 246.89 123.64 341.23 205.96 81.88 39.51 13.04 31.97
Shareholders Equity and Liabilities (Total)
234.52 281.15 276.74 181.54 451.14 469.55 328.92 282.62 246.42 63.36
Shares (Common)
70.80 93.69 104.58 105.17 154.79 156.26 164.52 227.17 255.94 265.05
Shareholders Equity (Tangible)
164.87 201.65 245.41 121.44 339.50 204.96 81.44 39.18 4.52 31.95
Net Debt
(181.47) (208.26) (205.13) (66.58) (347.28) (346.43) (184.26) (146.94) (101.37) (25.95)
Total Debt
— — — 22.97 20.94 23.15 20.35 — 50.24 —

Fold the line items

In millions of $ except per-share values · columns are period end dates